Related Experiment Video
Updated: May 29, 2025
04:05
Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
Published on: June 30, 2023
1.7K
Racial differences in diuretic therapy, B-type natriuretic peptide values, and prognosis in acute heart failure
Yu Horiuchi1, Yuya Matsue2, Nicholas Wettersten3
1Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.; Division of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan.
Journal of Cardiology
|February 1, 2025
Summary
B-type natriuretic peptide (BNP) levels vary by race in acute heart failure (AHF). A decrease in BNP after diuretic therapy predicts better prognosis for all races, aiding clinical integration of BNP testing.
Area of Science:
- Cardiology
- Biomarkers
- Heart Failure
Background:
- Race-based variability in B-type natriuretic peptide (BNP) may impact its clinical utility in acute heart failure (AHF).
- Understanding these differences is crucial for accurate interpretation of BNP as a marker for congestion and a predictor of prognosis.
Purpose of the Study:
- To investigate the relationship between diuretic therapy, changes in BNP levels, and prognosis in AHF across different racial groups.
- To determine if racial differences influence the association between BNP variability and clinical outcomes.
Main Methods:
- Combined data from the AKINESIS and REALITY-AHF studies, including White, Black, and Asian patients with AHF.
- Analyzed relative changes in BNP at 48 hours post-admission and its association with diuretic therapy and one-year mortality, adjusting for confounding factors.
Main Results:
- Black individuals had higher admission BNP values compared to White individuals.
- Asian individuals showed the greatest BNP decrease after diuretic therapy, predicting a better prognosis.
- BNP decrease was associated with lower one-year mortality across all races, irrespective of initial BNP levels.
Conclusions:
- Admission BNP levels are higher in Black patients with AHF.
- BNP decrease following diuretic treatment is more pronounced in Asian patients.
- A reduction in BNP levels is a universal predictor of improved prognosis in AHF, regardless of race.
Related Concept Videos
01:22Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
43
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
43
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375
01:22Heart Failure Drugs: β-Blockers
311
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
311
01:16Antihypertensive Drugs: Action of Diuretics
613
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
613
01:17Antihypertensive Drugs: Action of β1 Blockers
304
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
304